Chromium-picolinate therapy in diabetes care: Individual outcomes require new guidelines and navigation by predictive diagnostics

Infectious Disorders - Drug Targets

Volumn 12, Issue 5, 2012, Pages 332-339

  Yeghiazaryan, Kristina ^a   Schild, Hans H ^a   Golubnitschaja, Olga ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Chromium picolinate therapy; Diabetes care; Individual risks; Molecular patterns; Navigating diagnostics; New guidelines; Patient profiles; Personalised medicine; Subcellular imaging; Therapy response; Treatments tailored to patient

Indexed keywords

CHROMIUM PICOLINATE; COPPER ZINC SUPEROXIDE DISMUTASE; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE REGULATION; COMET ASSAY; CONTROLLED STUDY; DETOXIFICATION; DIABETES MELLITUS; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG MEGADOSE; EPIFLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TOXICITY; TREATMENT DURATION; WESTERN BLOTTING;

ANIMALS; COMET ASSAY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DNA BREAKS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MICE; PICOLINIC ACIDS; PRACTICE GUIDELINES AS TOPIC; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872229879     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152612804142215     Document Type: Article

References (40)

1. Golubnitschaja, O. Three Levels of Prediction, Prevention & Individualised Treatment Algorithms to Advance Diabetes Care: Integrative Approach. In the book New Strategies to Advance Pre/Diabetes Care: Integrative Approach by PPPM Ed. Mozaffari M.S. in the book series "Advances in Predictive, Preventive and Personalised Medicine", series Ed. Golubnitschaja O., Springer Dordrecht Heidelberg New York London 2012.
2. de la Monte, S. M. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs, 2012, 72, 49-66.
3. Rahim, M. A.; Hussain, A.; Azad Khan, A. K.; Sayeed, M. A.; Keramat Ali, S. M.; Vaaler, S. Rising prevalence of type 2 diabetes in rural Bangladesh: a population based study. Diabetes Res. Clin. Pract., 2007, 77, 300-305.
4. Nolan, J. J.; O'Halloran, D.; McKenna, T. J.; Firth, R.; Redmond, S. The cost of treating type 2 diabetes (CODEIRE). Ir. Med. J., 2006, 99, 307-310.
5. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 1047-1053.
6. Kowluru, V.; Kowluru, R. A. Increased oxidative stress in diabetes regulates activation of a small molecular weight G-protein, H-Ras, in the retina. Mol. Vis., 2007, 13, 602-610.
7. Azimi-Nezhad, M.; Ghayour-Mobarhan, M.; Parizadeh, M. R.; Safarian, M.; Esmaeili, H.; Parizadeh, S. M.; Khodaee, G.; Hosseini, J.; Abasalti, Z.; Hassankhani, B.; Ferns, G. Prevalence of type 2 diabetes mellitus in Iran and its relationship with gender, urbanisation, education, marital status and occupation. Singapore Med. J., 2008, 49, 571-576.
8. Cebioglu, M.; Golubnitschaja, O. New tendencies in the epidemiology of Diabetes mellitus. In Predictive Diagnostics and Personalized Treatment: Dream or Reality; Golubnitschaja, O., Ed.; Nova Science Publishers Inc: New York, 2009; pp. 151-156.
9. George, B.; Cebioglu, M.; Yeghiazaryan, K. Inadequate diabetic care: global figures cry for preventive measures and personalized treatment. EPMA J., 2010, 1, 13-18.
10. Connolly, V.; Unwin, N.; Sherriff, P.; Bilous, R.; Kelly, W. Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J. Epidemiol. Community Health, 2000, 54, 173-177.
11. Xu, F.; Yin, X. M.; Zhang, M.; Leslie, E.; Ware, R.; Owen, N. Family average income and diagnosed Type 2 diabetes in urban and rural residents in regional mainland China. Diabet. Med., 2006, 23, 1239-1246.
12. King, G. L. The role of inflammatory cytokines in diabetes and its complications. J. Periodontol., 2008, 79, 1527-1534.
13. Potenza, M. A.; Gagliardi, S.; Nacci, C.; Carratu', M. R.; Montagnani, M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr. Med. Chem., 2009, 16, 94-112.
14. Skljarevski, V.; Veves, A. Impact of diabetes on vasculature: focus on nervous system. Curr Diabetes Rev 2005, 1, 245-253.
15. Golubnitschaja, O. Advanced Diabetes care: three levels of prediction, prevention & personalized treatment. Curr. Diabetes Rev., 2010, 6, 42-51.
16. Yeghiazaryan, K.; Bauriedel, G.; Schild, H. H.; Golubnitschaja, O. Prediction of degeneration of native and bioprosthetic aortic valves: issue-related particularities of diabetes mellitus. Infect. Disord. Drug Targets, 2008, 8, 88-99.
17. Yeghiazaryan, K.; Skowasch, D.; Bauriedel, G.; Schild, H.; Golubnitschaja, O. Degenerative valve disease and bioprostheses: risk assessment, predictive diagnosis, personalised treatments. EPMA J., 2011, 2, 91-105.
18. Golubnitschaja, O. Clinical Proteomics in Application to Predictive Diagnostics and Personalized Treatment of Diabetic Patients. Curr. Proteomics, 2008, 5, 35-44.
19. Cebioglu, M.; Schild, H. H.; Golubnitschaja, O. Diabetes mellitus as a risk factor for cancer: stress or viral etiology? Infect. Disord. Drug Targets, 2008, 8, 76-87.
20. Cebioglu, M.; Schild, H. H.; Golubnitschaja, O. Diabetes mellitus as a Risk Factor for Cancer: Is Predictive Diagnosis Possible? In Predictive Diagnostics and Personalized Treatment: Dream or Reality?; Golubnitschaja, O., Ed.; Nova Science Publishers Inc: New York, 2009; pp. 247-262.
21. Cebioglu, M.; Schild, H.; Golubnitschaja, O. Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures. EPMA J., 2010, 1, 130-137.
22. Antić, M.; Jotić, A.; Radović, M.; Seferović, J. P.; Lalić, N. M.; Jovanović, D.; Lezaić, V. [Risk factors for the development of diabetic nephropathy]. Srp. Arh. Celok Lek., 2009, 137, 18-26.
23. Lewis, E. J.; Lewis, J. B. Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Clin. Exp. Nephrol., 2003, 7, 1-8.
24. Noh, J.-H.; Kim, S.-K.; Cho, Y.-J.; Nam, H.-U.; Kim, I.-J.; Jeong, I.-K.; Choi, M.-G.; Yoo, H.-J.; Ahn, Y.-H.; Bae, H.-Y.; Jang, H. C. Current status of diabetes management in elderly Koreans with diabetes. Diabetes Res. Clin. Pract., 2007, 77 Suppl. 1, S71-75.
25. Jana, M.; Rajaram, A.; Rajaram, R. Chromium picolinate induced apoptosis of lymphocytes and the signaling mechanisms thereof. Toxicol. Appl. Pharmacol., 2009, 237, 331-344.
26. Vincent, J. B. Elucidating a biological role for chromium at a molecular level. Acc. Chem. Res., 2000, 33, 503-510.
27. Andersson, M. A.; Petersson Grawé, K. V.; Karlsson, O. M.; Abramsson-Zetterberg, L. A. G.; Hellman, B. E. Evaluation of the potential genotoxicity of chromium picolinate in mammalian cells in vivo and in vitro. Food Chem. Toxicol., 2007, 45, 1097-1106.
28. Rhodes, M. C.; Hébert, C. D.; Herbert, R. A.; Morinello, E. J.; Roycroft, J. H.; Travlos, G. S.; Abdo, K. M. Absence of toxic effects in F344/N rats and B6C3F1 mice following subchronic administration of chromium picolinate monohydrate. Food Chem. Toxicol., 2005, 43, 21-29.
29. Bailey, M. M.; Sturdivant, J.; Jernigan, P. L.; Townsend, M. B.; Bushman, J.; Ankareddi, I.; Rasco, J. F.; Hood, R. D.; Vincent, J. B. Comparison of the potential for developmental toxicity of prenatal exposure to two dietary chromium supplements, chromium picolinate and [Cr3O(O2CCH2CH3)(6(H2O)3]+, in mice. Birth Defects Res. B Dev. Reprod. Toxicol., 2008, 83, 27-31.
30. Speetjens, J. K.; Collins, R. A.; Vincent, J. B.; Woski, S. A. The nutritional supplement chromium(III) tris(picolinate) cleaves DNA. Chem. Res. Toxicol., 1999, 12, 483-487.
31. Kareus, S. A.; Kelley, C.; Walton, H. S.; Sinclair, P. R. Release of Cr(III) from Cr(III) picolinate upon metabolic activation. J. Hazard. Mater., 2001, 84, 163-174.
32. Manygoats, K. R.; Yazzie, M.; Stearns, D. M. Ultrastructural damage in chromium picolinate-treated cells: a TEM study. Transmission electron microscopy. J. Biol. Inorg. Chem., 2002, 7, 791-798.
33. Stearns, D. M.; Silveira, S. M.; Wolf, K. K.; Luke, A. M. Chromium (III) tris(picolinate) is mutagenic at the hypoxanthine (guanine) phosphoribosyltransferase locus in Chinese hamster ovary cells. Mutat. Res., 2002, 513, 135-142.
34. Hepburn, D. D. D.; Xiao, J.; Bindom, S.; Vincent, J. B.; O'Donnell, J. Nutritional supplement chromium picolinate causes sterility and lethal mutations in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA, 2003, 100, 3766-3771.
35. Stallings, D. M.; Hepburn, D. D. D.; Hannah, M.; Vincent, J. B.; O'Donnell, J. Nutritional supplement chromium picolinate generates chromosomal aberrations and impedes progeny development in Drosophila melanogaster. Mutat. Res., 2006, 610, 101-113.
36. Golubnitschaja, O.; Moenkemann, H.; Kim, K.; Mozaffari, M. S. DNA damage and expression of checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in taurine-deficient cardiomyocytes. Biochem. Pharmacol., 2003, 66, 511-517.
37. Golubnitschaja, O. Diabetes mellitus. In Predictive Diagnostics and Personalized Treatment: Dream or Reality?; Golubnitschaja, O., Ed.; Nova Science Publishers Inc: New York, 2009; pp. 147-150.
38. Gahan, P. B. Circulating nucleic acids in plasma and serum: roles in diagnosis and prognosis in diabetes and cancer. Infect. Disord. Drug Targets, 2008, 8, 100-108.
39. Golubnitschaja, O.; Costigliola, V. Common origin but individual outcomes: time for new guidelines in personalized healthcare. Per. Med., 2010, 7, 561-568.
40. Yeghiazaryan, K.; Peeva, V.; Shenoy, A.; Schild, H. H.; Golubnitschaja, O. Chromium-picolinate therapy in diabetes care: molecular and subcellular profiling revealed a necessity for individual outcome prediction, personalised treatment algorithms and new guidelines. Infect. Disord. Drug Targets, 2011, 11, 188-195.